Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy
- 24 July 2005
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 357 (2) , 196-201
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Serum human glandular kallikrein (hK2) and insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSAThe Prostate, 2002
- Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissueUrology, 2000
- INTERPRETATION OF FREE PROSTATE SPECIFIC ANTIGEN CLINICAL RESEARCH STUDIES FOR THE DETECTION OF PROSTATE CANCERJournal of Urology, 1998
- Clinical utility of measurement free and total prostate-specific antigen (PSA): A reviewThe Prostate, 1996
- Alpha1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatc hyperplasiaUrology, 1994
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992
- Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate CancerJournal of Urology, 1992
- Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the ProstateJournal of Urology, 1991
- Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical ProstatectomyJournal of Urology, 1988
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987